Recent advances in recombinant protein-based malaria vaccines.
Silver Spring, United States. In Vaccine, Jan 2016
Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms.
The Ebola Virus matrix protein, VP40, requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) for extensive oligomerization at the plasma membrane and viral egress.
South Bend, United States. In Sci Rep, Dec 2015
Phosphatidylserine is required for VP40 plasma membrane binding, VP40 hexamer formation, and VLP egress, However, PS also becomes exposed on the outer membrane leaflet at sites of VP40 budding, raising the question of how VP40 maintains an interaction with the plasma membrane inner leaflet when PS is flipped to the opposite side.
Next generation prophylactic human papillomavirus vaccines.
Bethesda, United States. In Lancet Oncol, May 2015
The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe, effective, and well established prophylactic vaccines.
Lyon, France. In Unknown Journal, 0001
The potential of the current licensed preventive virus-like particle (VLP) human papillomavirus (HPV) vaccines to have a major public health impact is leading to additional clinical trials.